About Gan & Lee Pharmaceuticals. Company

The company was founded in 1998 and is a high-tech biopharmaceutical enterprise integrating scientific research, development, production and sales. As the first company in China to master the technology for industrial production of recombinant insulin analogs, Ganli Pharmaceutical is in a leading position in the Chinese diabetes market in developing and producing biosynthetic human insulin and its analogs, and has established close cooperation with well-known companies such as Sandoz (Sandoz) to actively explore overseas markets. As a global enterprise focusing on human health, Ganli Pharmaceutical adheres to a scientific and extreme corporate culture and is committed to providing high-quality products and services to diabetics around the world. The company is a high-tech enterprise mainly engaged in R&D, production and sales of insulin-like APIs and injections, and has a complete insulin research and development pipeline. The company's main products include glycine insulin injection (Changxiulin), laipulin insulin injection (Suxiulin), refined protein zinc recombinant laipuline insulin mixed injection (25R) (Suxiulin 25), mendong insulin injection (Rui Xiulin), mendong insulin 30 injection (Rui Xiulin 30), various insulin analogue products and sperm protein human insulin mixed injection (30R) (Puxulin 30). The products cover the three functional segments of the long-acting, quick-acting, and pre-mixed insulin. The company won the honorary title of Beijing Safety Culture Construction Demonstration Enterprise, won the China Pharmaceutical and Biological Industry Circuit Award, and won the National Intellectual Property Demonstration Enterprise Award in February 2023; the company won the 2022 Zhongguancun Listed Company Science and Technology Innovation Ranking, the 2023 China Top 50 Biopharmaceutical Research and Development Strength Ranking and the 2023 China Pharmaceutical Research and Development Comprehensive Strength Ranking. The company won the 2023 China Pharmaceutical Industry Comprehensive Competitiveness Index; the company was selected as the 2023 Beijing Top 100 Private Enterprise Science and Technology Innovation Index and Beijing Top 100 Private Enterprise Social Responsibility List, National High-tech Enterprise Qualification, Most Valuable Overseas Enterprise of the Year, Pharmaceutical Industry Excellence Award, and the 2023 Forbes China Best Innovative Practice Employer of the Year.